In vitro antihepadnaviral activities of combinations of penciclovir, lamivudine, and adefovir

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 3, 2000, Pages 551-560

  Colledge, Danni ^a   Civitico, Gilda ^a   Locarnini, Stephen ^a   Shaw, Tim ^a  

^a VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; FAMCICLOVIR; LAMIVUDINE; PENCICLOVIR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOSTASIS; CYTOTOXICITY; DRUG ACTIVITY; DRUG POTENTIATION; DUCK; HEPATITIS B VIRUS; IMMUNOMODULATION; LIVER CELL CULTURE; NONHUMAN; PRIORITY JOURNAL; VIRUS INHIBITION;

ACYCLOVIR; ADENINE; ANIMALS; ANTIVIRAL AGENTS; CELLS, CULTURED; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; DUCKS; HEPADNAVIRIDAE INFECTIONS; HEPATITIS B VIRUS, DUCK; HUMANS; LAMIVUDINE; LIVER; PHOSPHONIC ACIDS; VIRUS REPLICATION;

EID: 0033999389     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.3.551-560.2000     Document Type: Article

References (41)

1. Allen, M. I., M. Deslauriers, C. W. Andrews, G. A. Tipples, K. A. Walters, D. L. Tyrrell, N. Brown, and L. D. Condreay. 1998. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 27:1670-1677.
2. Annaert, P., R. Kinget, L. Naesens, E. de Clercq, and P. Augustijns. 1997. Transport, uptake, and metabolism of the bis(pivaloyloxymethyl)-ester prodrug of 9-(2-phosphonylmethoxyethyl)adenine in an in vitro cell culture system of the intestinal mucosa (Caco-2). Pharm. Res. 14:492-496.
3. Aye, T. T., A. Bartholomeusz, T. Shaw, S. Bowden, A. Breschkin, J. McMillan, P. Angus, and S. Locarnini. 1997. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. J. Hepatol. 26:1148-1153.
4. Barditch-Crovo, P., J. Toole, C. W. Hendrix, K. C. Cundy, D. Ebeling, H. S. Jaffe, and P. S. Lietman. 1997. Anti-human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxil (9-[2-(bis-pivaloyloxymethyl)-phosphonylmethoxyethyl]adenine) in HIV-infected patients. J. Infect. Dis. 176:406-413.
5. Berenbaum, M. C. 1989. What is synergy? Pharmacol. Rev. 41:93-141.
6. Boni, C., A. Bertoletti, A. Penna, A. Cavalli, M. Pilli, S. Urbani, P. Scognamiglio, R. Boehme, R. Panebianco, F. Fiaccadori, and C. Ferrari. 1998. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J. Clin. Investig. 102:968-975.
7. Civitico, G., Y. Wang, C. Luscombe, N. Bishop, G. Tachedjian, I. Gust, and S. Locarnini. 1990. Antiviral strategies in chronic hepatitis B virus infection. II. Inhibition of duck hepatitis B virus in vitro using conventional antiviral agents and supercoiled-DNA active compounds. J. Med. Virol. 31:90-97.
8. Civitico, G. M., and S. A. Locarnini. 1994. The half-life of duck hepatitis B virus supercoiled DNA in congenitally infected primary hepatocyte cultures. Virology 203:81-89.
9. Cohen Stuart, J. W., C. A. Boucher, D. A. Cooper, G. J. Galasso, D. D. Richman, H. C. Thomas, and R. J. Whitley. 1998. Summary of the Third International Consensus Symposium on Combined Antiviral Therapy. Antivir. Res. 38:75-93.
10. Colacino, J. M., and K. A. Staschke. 1998. The identification and development of antiviral agents for the treatment of chronic hepatitis B virus infection. Prog. Drug Res. 50:259-322.
11. Colledge, D., S. Locarnini, and T. Shaw. 1997. Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro. Hepatology 26:216-225.
12. Danniaoui, E., C. Trepo, and F. Zoulim. 1997. Inhibitory effect of penciclovir-triphosphate on duck hepatitis B virus reverse transcription. Antivir. Chem. Chemother. 8:38-46.
13. Deeks, S. G., A. Collier, J. Lalezari, A. Pavia, D. Rodrigue, W. L. Drew, J. Toole, H. S. Jaffe, A. S. Mulato, P. D. Lamy, W. Li, J. M. Cherrington, N. Hellmann, and J. Kahn. 1997. The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial. J. Infect. Dis. 176:1517-1523.
14. Del Gobbo, V., A. Foli, J. Balzarini, E. De Clercq, E. Balestra, N. Villani, S. Marini, C. F. Perno, and R. Calio. 1991. Immunomodulatory activity of 9-(2-phosphonylmethoxyethyl)adenine (PMEA), a potent anti-HIV nucleotide analogue, on in vivo murine models. Antivir. Res. 16:65-75.
15. Dienstag, J. L., R. P. Perrillo, E. R. Schilf, M. Bartholomew, C. Vicary, and M. Rubin. 1995. A preliminary trial of lamivudine for chronic hepatitis B infection. N. Engl. J. Med. 333:1657-1661.
16. Fagan, E. A., E. Lausch, D. Rowell, S. Tekankornpul, H. Rosenblate, D. Ganger, and D. Jensen. 1997. Improvement in protracted complicated hepatitis B with reduction in residual virus replication using lamivudine/famciclovir. Hepatology 26(Suppl.):504A. (Abstract 1502.)
17. Fourel, I., P. Gripon, O. Hantz, L. Cova, V. Lambert, C. Jacquet, K. Watanabe, J. Fox, C. Guillouzo, and C. Trepo. 1989. Prolonged duck hepatitis B virus replication in duck hepatocytes cocultivated with rat epithelial cells: a useful system for antiviral testing. Hepatology 10:186-191.
18. Gilson, R. J. C., I. M. Murray-Lyon, M. R. Nelson, S. J. Rice, R. S. Tedder, A. Murray, H. S. Jaffe, N. Hellmann, and I. V. D. Weller. 1998. Extended treatment with adefovir dipivoxil in patients with chronic hepatitis B virus infection. Hepatology 28(Suppl.):491A. (Abstract 1316.)
19. Greco, W. R., G. Bravo, and J. C. Parsons. 1995. The search for synergy: a critical review from a response surface perspective. Pharmacol. Rev. 47:331-385.
20. Heathcote, E. J., L. Jeffers, T. Wright, M. Sherman, R. Perillo, S. Sacks, R. Carithers, V. Rustgi, A. Di Bisceglie, V. Balan, A. Murray, J. Rooney, and H. S. Jaffe. 1998. Loss of serum HBV DNA and HBeAg and seroconversion following short-term (12 weeks) adefovir dipovoxil therapy in chronic hepatitis B: two placebo-controlled phase II studies. Hepatology 28(Suppl.): 317A. (Abstract 1316.)
21. Heijtink, R. A., G. A. De Wilde, J. Kruining, L. Berk, J. Balzarini, E. De Clercq, A. Holy, and S. W. Schalm. 1993. Inhibitory effect of 9-(2-phosphonylmethoxyethyl)-adenine (PMEA) on human and duck hepatitis B virus infection. Antivir. Res. 21:141-153.
22. Heijtink, R. A., J. Kruining, G. A. de Wilde, J. Balzarini, E. de Clercq, and S. W. Schalm. 1994. Inhibitory effects of acyclic nucleoside phosphonates on human hepatitis B virus and duck hepatitis B virus infections in tissue culture. Antimicrob. Agents Chemother. 38:2180-2182.
23. Hoofnagle, J. H. 1998. Therapy of viral hepatitis. Digestion 59:563-578.
24. Lai, C. L., R. N. Chien, N. W. Leung, T. T. Chang, R. Guan, D. I. Tai, K. Y. Ng, P. C. Wu, J. C. Dent, J. Barber, S. L. Stephenson, and D. F. Gray. 1998. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N. Engl. J. Med. 339:61-68.
25. Lai, C. L., M. F. Yeun, C. C. Cheng, W. M. Wong, T. K. Cheng, and Y. P. Lai. 1998. An open comparative study of lamivudine and famciclovir in the treatment of chronic hepatitis B. Hepatology 27(Suppl.):318A. (Abstract 622.)
26. Lin, E., C. Luscombe, Y. Y. Wang, T. Shaw, and S. Locarnini. 1996. The guanine nucleoside analog penciclovir is active against chronic duck hepatitis B virus infection in vivo. Antimicrob. Agents Chemother. 40:413-418.
27. Main, J., J. L. Brown, C. Howells, R. Galassini, M. Crossey, P. Karayiannis, P. Georgiou, G. Atkinson, and H. C. Thomas. 1996. A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. J. Viral Hepatitis 3:211-215.
28. Naesens, L., R. Snoeck, G. Andrei, J. Balzarini, and E. De Clercq. 1998. HPMPC (cidofovir), PMEA (adefovir) and related acyclic nucleoside phosphonate analogues: a review of their pharmacology and clinical potential in the treatment of viral infections. Antivir. Chem. Chemother. 8:1-23.
29. Nicoll, A. J., P. W. Angus, S. T. Chou, C. A. Luscombe, R. A. Smallwood, and S. A. Locarnini. 1997. Demonstration of duck hepatitis B virus in bile duct epithelial cells: implications for pathogenesis and persistent infection. Hepatology 25:463-469.
30. Nicoll, A. J., D. L. Colledge, J. J. Toole, P. W. Angus, R. A. Smallwood, and S. A. Locarnini. 1998. Inhibition of duck hepatitis B virus replication by 9-(2-phosphonylmethoxyethyl)adenine, an acyclic phosphonate nucleoside analogue. Antimicrob. Agents Chemother. 42:3130-3135.
31. Shaw, T., P. Amor, G. Civitico, M. Boyd, and S. Locarnini. 1994. In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus. Antimicrob. Agents Chemother. 38:719-723.
32. Shaw, T., and S. Locarnini. 1995. Hepatic purine and pyrimidine metabolism: implications for antiviral chemotherapy in viral hepatitis. Liver 15:169-184.
33. Shaw, T., and S. Locarnini. 1999. Preclinical aspects of lamivudine and famciclovir against hepatitis B virus. J. Viral Hepatitis 6:89-106.
34. Shaw, T., D. Colledge, and S. A. Locarnini. 1997. Synergistic inhibition of in vitro hepadnaviral replication by PMEA and penciclovir or lamivudine. Antivir. Res. 34:A51. (Abstract 33.)
35. Shaw, T., S. S. Mok, and S. A. Locarnini. 1996. Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir. Hepatology 24:996-1002.
36. Sherker, A., and P. Marion. 1991. Hepadnaviruses and hepatocellular carcinoma. Annu. Rev. Microbiol. 45:475-508.
37. Tillman, H. L., C. Trautwein, T. Bock, M. Glowenka, M. Kruger, K. Boker, E. Jakel, R. Pilchmayr, L. Condreay, J. Bruns, M. Desjaurias, J. Gauthier, and M. P. Manns. 1997. Response and mutations in patients sequentially treated with lamivudine and famciclovir for recurrent hepatitis B after liver transplantation. Hepatology 26(Suppl.):429A. (Abstract 1202.)
38. Tuttleman, J. S., J. C. Pugh, and J. W. Summers. 1986. In vitro experimental infection of primary duck hepatocyte cultures with duck hepatitis B virus. J. Virol. 58:17-25.
39. Wu, T. T., L. Coates, C. E. Aldrich, J. Summers, and W. S. Mason. 1990. In hepatocytes infected with duck hepatitis B virus, the template for viral RNA synthesis is amplified by an intracellular pathway. Virology 175:255-261.
40. Xiong, X., C. Flores, H. Yang, J. J. Toole, and C. S. Gibbs. 1998. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 28:1669-1673.
41. Zoulim, F., and C. Trepo. 1998. Drug therapy for chronic hepatitis B: antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy. J. Hepatol. 29:151-168.